Is Unity Software a Buy Now?
Unity Software (NYSE:U) is the company behind the popular Unity…
Buy
65
BCPC Quote, Financials, Valuation and Earnings
Last price:
$168.38
Seasonality move
:
6.65%
Day range:
$165.62 - $168.86
52-week range:
$145.70 - $186.03
Dividend yield:
0.52%
P/E ratio:
40.07x
P/S ratio:
5.68x
P/B ratio:
4.51x
Volume:
194.1K
Avg. volume:
198.1K
1-year change:
7.43%
Market cap:
$5.5B
Revenue:
$953.7M
EPS (TTM):
$4.17
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Balchem has 17.29% upside to fair value with a price target of $196.00 per share.
BCPC vs. S&P 500
-
Over the past 5 trading days, Balchem has underperformed the S&P 500 by -3.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Balchem does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Balchem has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Balchem reported revenues of $250.5M.
Earnings Growth
-
Balchem has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Balchem reported earnings per share of $1.13.
Enterprise value:
5.6B
EV / Invested capital:
4.00x
Price / LTM sales:
5.68x
EV / EBIT:
29.18x
EV / Revenue:
5.80x
PEG ratio (5yr expected):
2.25x
EV / Free cash flow:
37.08x
Price / Operating cash flow:
36.32x
Enterprise value / EBITDA:
23.60x
Gross Profit (TTM):
$342.9M
Return On Assets:
8.58%
Net Income Margin (TTM):
14.16%
Return On Equity:
11.92%
Return On Invested Capital:
9.89%
Operating Margin:
20.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $946M | $929.6M | $964.5M | $239.7M | $250.5M | |
| Gross Profit | $282.1M | $310.4M | $342.9M | $81.5M | $88.2M | |
| Operating Income | $141.3M | $166.5M | $192.2M | $41.7M | $51M | |
| EBITDA | $194.1M | $222.4M | $236.9M | $55.9M | $61.9M | |
| Diluted EPS | $3.06 | $3.54 | $4.17 | $0.89 | $1.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $281.2M | $319.8M | $335.6M | $324.9M | $340.2M | |
| Total Assets | $1.2B | $1.2B | $1.6B | $1.6B | $1.6B | |
| Current Liabilities | $88.8M | $123.5M | $116.5M | $124.4M | $139.6M | |
| Total Liabilities | $319.7M | $321.2M | $655.3M | $509.9M | $408.9M | |
| Total Equity | $849.5M | $873.7M | $973.4M | $1.1B | $1.2B | |
| Total Debt | $153.6M | $128.6M | $431.6M | $301.6M | $190M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $166.4M | $182.3M | $185.1M | $33.4M | $36.5M | |
| Cash From Investing | -$416M | -$31.5M | -$58.9M | -$6.7M | -$5.9M | |
| Cash From Financing | $248.2M | -$150M | -$135.8M | -$30M | -$32M | |
| Free Cash Flow | $117M | $147.2M | $150.8M | $26.5M | $30.9M | |
BCPC
Sector
Market Cap
$5.5B
$18.1M
Price % of 52-Week High
89.83%
63.06%
Dividend Yield
0.52%
0%
Shareholder Yield
1.07%
1.05%
1-Year Price Total Return
6.88%
-16.67%
Beta (5-Year)
0.933
0.776
Dividend yield:
0.52%
Annualized payout:
$0.87
Payout ratio:
20.72%
Growth streak:
15 years
Technicals
8-day SMA
Buy
Level
$165.37
200-day SMA
Buy
Level
$168.08
Bollinger Bands (100)
Buy
Level
157.82 - 168.04
Chaikin Money Flow
Buy
Level
30.3M
20-day SMA
Buy
Level
$160.87
Relative Strength Index (RSI14)
Buy
Level
62.60
ADX Line
Buy
Level
16.38
Williams %R
Sell
Level
-10.8125
50-day SMA
Buy
Level
$162.69
MACD (12, 26)
Buy
Level
1.56
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
27.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.4708)
Buy
CA Score
(Annual)
Level (1.1845)
Buy
Beneish M-Score
(Annual)
Level (-2.636)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.2069)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Stock Forecast FAQ
In the current month, BCPC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCPC average analyst price target in the past 3 months is $196.00.
-
Where Will Balchem Stock Be In 1 Year?
According to analysts, the consensus estimate is that Balchem share price will rise to $196.00 per share over the next 12 months.
-
What Do Analysts Say About Balchem?
Analysts are divided on their view about Balchem share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Balchem is a Sell and believe this share price will drop from its current level to $180.00.
-
What Is Balchem's Price Target?
The price target for Balchem over the next 1-year time period is forecast to be $196.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCPC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Balchem is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BCPC?
You can purchase shares of Balchem via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Balchem shares.
-
What Is The Balchem Share Price Today?
Balchem was last trading at $168.38 per share. This represents the most recent stock quote for Balchem. Yesterday, Balchem closed at $168.26 per share.
-
How To Buy Balchem Stock Online?
In order to purchase Balchem stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock 5X?
Uber (NYSE:UBER) has generated extremely strong returns for its investors…
How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
59
RGC alert for May 16
Regencell Bioscience Holdings [RGC] is down 4.18% over the past day.
Buy
89
BOOT alert for May 17
Boot Barn Holdings [BOOT] is up 1.14% over the past day.
Buy
80
NTES alert for May 16
NetEase [NTES] is down 2.62% over the past day.
